STOCK TITAN
  1. Home
  2. Sec-filings
  3. NBP
  4. [Form 3] NovaBridge Biosciences Initial Statement of Beneficial Ownership

NovaBridge Biosciences (NBP) director reports option and RSU equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

NovaBridge Biosciences director Lenz Robert A. has reported his existing equity awards in the company. He holds a 2025 employee share option covering 19,130 underlying securities with an exercise price of $5.09 per ADS, expiring on August 22, 2035, vesting in three equal annual installments starting on the first anniversary of the August 22, 2025 grant date. He also holds 22,460 restricted share units, each representing a contingent right to receive one ADS, vesting in three equal annual installments on August 22, 2026, 2027 and 2028. These entries reflect compensation-related awards rather than open-market share purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Lenz Robert A.
Role Director
Type Security Shares Price Value
holding 2025 Employee Share Option (right to buy) -- -- --
holding Restricted Share Units -- -- --
Holdings After Transaction: 2025 Employee Share Option (right to buy) — 19,130 shares (Direct); Restricted Share Units — 22,460 shares (Direct)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Number of underlying securities and exercise price expressed in terms of ADSs. The option was granted on August 22, 2025.The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date. On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028.
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Lenz Robert A.
(Last)(First)(Middle)
C/O NOVABRIDGE BIOSCIENCES,
2440 RESEARCH BOULEVARD, SUITE 400
(Street)
ROCKVILLE MARYLAND 20850
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
2025 Employee Share Option (right to buy) (3)08/22/2035Ordinary Shares(1)19,130(2)$5.09(2)D
Restricted Share Units (4) (4)Ordinary Shares(1)22,460(2)(4)D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
2. Number of underlying securities and exercise price expressed in terms of ADSs.
3. The option was granted on August 22, 2025.The option vests and becomes exercisable in three equal annual installments beginning on the first anniversary of the grant date.
4. On August 22, 2025, the Reporting Person was granted 22,460 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vest over three years in three equal annual installments on August 22, 2026, 2027 and 2028.
Remarks:
Exhibit List: Ex. 24.1- Power of Attorney
/s/ Xi-Yong (Sean) Fu as attorney-in-fact03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider holdings did Lenz Robert A. report in NovaBridge Biosciences (NBP)?

Lenz Robert A. reported holdings of employee share options and restricted share units in NovaBridge Biosciences. The options cover 19,130 underlying securities, and he also holds 22,460 RSUs, all relating to the company’s American Depositary Shares (ADSs).

What are the key terms of the 2025 employee share option reported for NBP?

The 2025 employee share option has an exercise price of $5.09 per ADS and expires on August 22, 2035. It was granted on August 22, 2025 and vests in three equal annual installments beginning on the first anniversary of that grant date.

How many restricted share units does the NovaBridge Biosciences director hold?

The director holds 22,460 restricted share units. Each RSU represents a contingent right to receive one ADS of NovaBridge Biosciences, vesting over three years in three equal annual installments on August 22, 2026, 2027 and 2028.

Do the reported NovaBridge Biosciences insider entries show any share purchases or sales?

No, the entries reflect existing holdings of options and RSUs, not open-market trades. The transaction summary shows no buy or sell transactions, only holding entries, indicating compensation-related equity awards rather than current purchases or disposals.

How are NovaBridge Biosciences Ordinary Shares represented in American Depositary Shares?

The company’s Ordinary Shares may be represented by American Depositary Shares (ADSs). According to the disclosure, each 10 ADSs represent 23 Ordinary Shares, and the underlying security numbers and exercise price are expressed in terms of ADSs.

What vesting schedule applies to the RSUs reported for NovaBridge Biosciences (NBP)?

The RSUs were granted on August 22, 2025 and vest over three years. Vesting occurs in three equal annual installments on August 22, 2026, August 22, 2027 and August 22, 2028, each installment covering one-third of the 22,460 RSUs.